Sodium/calcium exchanger as main effector of endogenous neuroprotection elicited by ischemic tolerance.

Cell Calcium

Division of Pharmacology, Department of Neuroscience, School of Medicine, University of Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.

Published: May 2020

AI Article Synopsis

  • The ischemic tolerance (IT) paradigm is a biological response that makes organs more resistant to subsequent injuries following a mild initial insult, first noted by Paracelsus in the 16th century with the idea that "the dose makes the poison."
  • In the early 1990s, it was demonstrated in gerbils that brief periods of subthreshold brain ischemia could protect against more severe ischemic events, allowing for categorization based on timing as preconditioning, perconditioning, and postconditioning.
  • The review focuses on how specific membrane proteins aid in ionic balance and provide protection during brain conditioning, detailing the underlying molecular mechanisms that enable brain cells to adapt to low oxygen conditions.

Article Abstract

The ischemic tolerance (IT) paradigm represents a fundamental cell response to certain types or injury able to render an organ more "tolerant" to a subsequent, stronger, insult. During the 16th century, the toxicologist Paracelsus described for the first time the possibility that a noxious event might determine a state of tolerance. This finding was summarized in one of his most important mentions: "The dose makes the poison". In more recent years, ischemic tolerance in the brain was first described in 1991, when it was demonstrated by Kirino and collaborators that two minutes of subthreshold brain ischemia in gerbils produced tolerance against global brain ischemia. Based on the time in which the conditioning stimulus is applied, it is possible to define preconditioning, perconditioning and postconditioning, when the subthreshold insult is applied before, during or after the ischemic event, respectively. Furthermore, depending on the temporal delay from the ischemic event, two different modalities are distinguished: rapid or delayed preconditioning and postconditioning. Finally, the circumstance in which the conditioning stimulus is applied on an organ distant from the brain is referred as remote conditioning. Over the years the "conditioning" paradigm has been applied to several brain disorders and a number of molecular mechanisms taking part to these protective processes have been described. The mechanisms are usually classified in three distinct categories identified as triggers, mediators and effectors. As concerns the putative effectors, it has been hypothesized that brain cells appear to have the ability to adapt to hypoxia by reducing their energy demand through modulation of ion channels and transporters, which delays anoxic depolarization. The purpose of the present review is to summarize the role played by plasmamembrane proteins able to control ionic homeostasis in mediating protection elicited by brain conditioning, particular attention will be deserved to the role played by Na/Ca exchanger.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ceca.2020.102183DOI Listing

Publication Analysis

Top Keywords

ischemic tolerance
12
brain ischemia
8
conditioning stimulus
8
stimulus applied
8
ischemic event
8
role played
8
brain
7
ischemic
5
tolerance
5
sodium/calcium exchanger
4

Similar Publications

The duodenal diverticulum is a relatively frequent entity whose diagnosis has been increased over time with the development of new diagnostic and exploratory techniques. Periampullary diverticula (PAD) were classified as type 1, 2, or 3 according to the position of the major papilla from the endoscopic view: type 1, the major papilla was located inside of the diverticula; type 2, the major papilla was located at the edge of the diverticula; type 3, the major papilla was located outside of the diverticula. Complications of duodenal diverticula include ulceration, bleeding, perforation and inflammation with intestinal obstruction.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Biomed Industries, Inc., San Jose, CA, USA.

Background: NA-831 is a candidate for the treatment of Alzheimer's Disease (AD). NA-911 is an analog of NA-831, serving as an IGF-1 and GLP-1 agonists. Animal studies of NA-911 are evaluated for the treatment of by hypoxic-ischemic injury, hemorrhagic stroke, and chronic neurodegenerative disorders METHOD: For NA-831: A randomized clinical trial of NA-831 was performed in 112 participants with mild and moderate AD, half received the drugs and half received placebo.

View Article and Find Full Text PDF

: Central and branch retinal artery occlusion (CRAO and BRAO) are critical causes of acute vision loss, predominantly affecting older adults with systemic vascular pathology. These occlusions typically result from embolic events, leading to partial or complete retinal ischemia. : This retrospective case series report details of our 10-year experience using the 1064 nm Nd:YAG laser for Transluminal Nd:YAG Embolysis (TYE) in order to lyse visible emboli within the retinal arteries.

View Article and Find Full Text PDF

Unlabelled: Numerous studies highlight the significant role of exercise therapy in patients with peripheral artery disease (PAD), emphasizing how regular physical exercise enhances vascular endothelial function and promotes metabolic adaptations in skeletal muscles, ultimately improving walking performance. There are currently discussions in the medical world on optimizing noninvasive therapy to prevent the development of lower limb ischemia. This study aimed to assess the impact of a supervised training program combined with whirlpool massage treatment on improving peripheral circulation and physical performance in patients suffering from peripheral artery disease.

View Article and Find Full Text PDF

Background: Low-density lipoprotein cholesterol (LDL-C) has been determined as an established risk factor for acute ischemic stroke (AIS). Despite the recommendation for in-hospital initiation of high-intensity statin therapy in AIS patients, achieving the desired target LDL-C levels remains challenging. Evolocumab, a highly effective and quickly acting agent for reducing LDL-C levels, has yet to undergo extensively exploration in the acute phase of AIS.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!